In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on BridgeBio Pharma (BBIO), with a price target of $86.00. The company’s shares closed last Monday at $46.47.
According to TipRanks.com, Syed is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.7% and a 42.0% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Assembly Biosciences, and Coherus Biosciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BridgeBio Pharma with a $80.43 average price target, a 69.4% upside from current levels. In a report issued on May 7, Goldman Sachs also maintained a Buy rating on the stock with a $80.00 price target.
See today’s analyst top recommended stocks >>
Based on BridgeBio Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $122K and GAAP net loss of $120 million. In comparison, last year the company earned revenue of $13.82 million and had a GAAP net loss of $73.46 million.
Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BBIO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
